- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03792750
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Local Institution
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1
- Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting
- Participants must have an ECOG performance status of less than or equal to 1
- Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1
Exclusion Criteria:
- Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
- Participants with prior exposure to anti PD-1 or anti-PDL1 therapy
- Participants must not have a history of allergy to any of the study treatment components
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Experimental Arm A
2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
|
Specified Dose on Specified Day
Specified Dose on Specified Day
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The Number of Participants Experiencing Adverse Events (AE)
Zeitfenster: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing adverse events (AEs) to assess the safety and tolerability of BMS-986205. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experiencing Serious Adverse Events (SAE)
Zeitfenster: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing serious adverse events (SAEs) to assess the safety and tolerability of BMS-986205 Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experience Adverse Events (AE) Leading to Discontinuation
Zeitfenster: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing adverse events (AEs) leading to discontinuation to assess the safety and tolerability of BMS-986205 An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
Number of Participant Deaths
Zeitfenster: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants who died in each arm during the study to assess the safety and tolerability of BMS-986205.
|
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
Zeitfenster: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units to assess the safety and tolerability of BMS-986205. The number of participants with the following laboratory abnormalities will be summarized: ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN Total bilirubin > 1.5 x ULN and 2 x ULN Concurrent (within 1 day) ALT or AST > 3 x ULN with total bilirubin > 2 x ULN Concurrent (within 30 days) ALT or AST > 3 x ULN with total bilirubin > 2 x ULN |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
Zeitfenster: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants with clinical laboratory test abnormalities based on US conventional units to assess the safety and tolerability of BMS-986205. The number of subjects with the following laboratory abnormalities will be summarized: TSH > ULN WITH TSH <= ULN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date) TSH < LLN WITH TSH >= LLN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date) |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
(Cmax) Maximum Observed Plasma Concentration
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The maximum observes plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
(Tmax) Time of Maximum Observed Plasma Concentration
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The time of maximum observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
(AUC(TAU)) Area Under the Concentration-time Curve in One Dosing Interval
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The area under the concentration-time curve in one dosing interval was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
(CLT/F) Apparent Total Body Clearance
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14, Cycle 1 day 1
|
The apparent total body clearance was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14, Cycle 1 day 1
|
(T-HALF (Eff, AUC)) Effective Elimination Half-life
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The effective elimination half-life was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
T-HALF (eff, AUC) explains the degree of AUC accumulation observed.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
(AI_CMAX) Accumulation Index
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
AI is calculated based on ratio of Cmax at steady state to after the first dose.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
(AI_AUC ) Accumulation Index
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
AI is calculated based on ratio of AUC(TAU) at steady state to after the first dose.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
(Ctrough) Trough Observed Plasma Concentration
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 2, 8, 14, Cycle 1 day 1, 2, Cycle 3, 5, 9, 13, and 17 day 1
|
The trough observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 2, 8, 14, Cycle 1 day 1, 2, Cycle 3, 5, 9, 13, and 17 day 1
|
(percentUR24) Percent Urinary Recovery Over 24 Hours
Zeitfenster: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 Day 1 and 2
|
The percent urinary recovery over 24 hours was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab. BMS-986205 had minimal evaluable concentration in urine to derive the parameter. |
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 Day 1 and 2
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Objective Response Rate (ORR)
Zeitfenster: From first dose up to approximately 2 years
|
ORR is defined as the total number of participants whose best overall response (BOR) is either a completer response (CR) or partial response (PR) divided by the total number of participants in the population of interest. Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator BOR is defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. |
From first dose up to approximately 2 years
|
Best Overall Response (BOR)
Zeitfenster: From first dose up to approximately 2 years
|
BOR defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy.
Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator
|
From first dose up to approximately 2 years
|
Duration of Response (DOR)
Zeitfenster: From first dose up to approximately 2 years
|
Duration of Response (DOR) is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first.
Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator.
|
From first dose up to approximately 2 years
|
Measurement of Serum Kynurenine Levels
Zeitfenster: Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of kynurenine levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
|
Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of Tryptophan Levels
Zeitfenster: Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of tryptophan levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
|
Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Number of Participants With Anti-drug Antibodies (ADA) to Nivolumab
Zeitfenster: Baseline, pre-dose (C1D1, C3D1, every 4 Cycles from C5D1), end of treatment - an average of 12 cycles, and follow up. (up to approximately 2 years)
|
The number of participants with positive or negative anti-drug antibodies (ADA) to nivolumab was collected to characterize the immunogenicity of nivolumab when administered in combination with BMS-986205. Baseline ADA Positive: A subject with baseline ADA-positive sample. ADA Positive: A subject with at least one ADA-positive sample relative to baseline. Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline ADA Negative: A subject with no ADA-positive sample after initiation of treatment. |
Baseline, pre-dose (C1D1, C3D1, every 4 Cycles from C5D1), end of treatment - an average of 12 cycles, and follow up. (up to approximately 2 years)
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CA017-076
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fortgeschrittener Krebs
-
Extremity MedicalRekrutierungArthrose | Entzündliche Arthritis | Karpaltunnelsyndrom (CTS) | Posttraumatische Arthritis | Scapholunate Advanced Collapse (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapezium und Trapezoid Advanced Collapse (STTAC) | Kienbock-Krankheit des Erwachsenen | Radiale Malunion | Ulnare Translokation und andere BedingungenVereinigte Staaten
-
Northwell HealthZurückgezogenDiabetes | SGLT-2-Inhibitoren | Advanced Glycation End-Produkte
-
Advanced BionicsAbgeschlossenSchwerer bis hochgradiger Hörverlust | bei erwachsenen Benutzern des Advanced Bionics HiResolution™ Bionic Ear SystemVereinigte Staaten
-
Töölö HospitalTurku University Hospital; Tampere University Hospital; Jyväskylä Central Hospital und andere MitarbeiterRekrutierungArthrose am Handgelenk | Scapholunate Advanced CollapseFinnland
-
University of AlbertaArthritis Society Canada; Wrist Evaluation Canada (WECAN)RekrutierungArthritis | Gelenkerkrankungen | Erkrankungen des Bewegungsapparates | Posttraumatisch; Arthrose | Arthrose am Handgelenk | Kahnbein-Pseudarthrose | Scapholunate Advanced Collapse | Arthropathie am HandgelenkKanada
-
The Leeds Teaching Hospitals NHS TrustAktiv, nicht rekrutierendWunden und Verletzungen | Chirurgie | Rehabilitation | Orthopädische Störung | Vom Patienten gemeldete Ergebnismessungen | Bewertung der Behinderung | Wiederherstellung der Funktion | Mehrere Traumata/Verletzungen | Traumazentren | Trauma-Schwere-Indizes | Advanced Trauma Life Support CareVereinigtes Königreich
-
Maastricht University Medical CenterAbgeschlossenDiät | Gefäßfunktion | Insulinsensitivität/-resistenz | Beta-Zell-Funktion | Advanced Glycation End-Produkte | ALTERNiederlande
-
TakedaAktiv, nicht rekrutierendALK+ Advanced NSCLCSpanien, China, Korea, Republik von, Taiwan, Hongkong, Thailand, Italien, Rumänien, Vereinigte Staaten, Mexiko, Kroatien, Russische Föderation, Argentinien, Kanada, Deutschland, Frankreich, Österreich, Chile, Griechenland, Sch...
-
QIAGEN Gaithersburg, IncAbgeschlossenRespiratory-Syncytial-Virus-Infektionen | Grippe A | Rhinovirus | Influenza B | QIAGEN ResPlex II Advanced Panel | Infektion durch das humane Parainfluenzavirus 1 | Parainfluenza Typ 2 | Parainfluenza Typ 3 | Parainfluenza Typ 4 | Humanes Metapneumovirus A/B | Coxsackie-Virus/Echovirus | Adenovirus-Typen B... und andere BedingungenVereinigte Staaten
Klinische Studien zur BMS-986205
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)BeendetNicht resezierbares hepatozelluläres Karzinom | Hepatozelluläres Karzinom Stadium III AJCC v8 | Hepatozelluläres Karzinom im Stadium IIIA AJCC v8 | Stadium IV hepatozelluläres Karzinom AJCC v8 | Hepatozelluläres Karzinom im Stadium IVA AJCC v8 | Hepatozelluläres Karzinom im Stadium IVB AJCC... und andere BedingungenVereinigte Staaten
-
Thomas Jefferson UniversityBristol-Myers SquibbAktiv, nicht rekrutierendLarynx | Plattenepithelkarzinom | Lippe | Plattenepithelkarzinom der Mundhöhle | RachenVereinigte Staaten
-
Bristol-Myers SquibbAbgeschlossenMelanom | HautkrebsVereinigte Staaten, Kanada, Niederlande, Spanien, Australien, Italien, Japan, Deutschland, Irland, Vereinigtes Königreich, Tschechien, Schweiz, Polen, Frankreich, Griechenland, Neuseeland
-
Northwestern UniversityNational Cancer Institute (NCI)Aktiv, nicht rekrutierend
-
PDL BioPharma, Inc.BeendetColitis ulcerosaBelgien, Frankreich, Vereinigte Staaten, Italien, Australien, Tschechische Republik, Niederlande, Irland, Norwegen, Kanada, Österreich, Deutschland, Ungarn, Ukraine
-
Bristol-Myers SquibbAbgeschlossen
-
Bristol-Myers SquibbAbgeschlossen
-
Bristol-Myers SquibbAbgeschlossenGesunde TeilnehmerVereinigtes Königreich
-
Bristol-Myers SquibbAbgeschlossenFortgeschrittener KrebsVereinigte Staaten, Israel, Australien, Österreich, Kanada, Italien
-
National Alliance on Mental Illness New HampshireJanssen Medical AffairsBeendetPsychotische StörungenVereinigte Staaten